BioArctic’s Leqembi gets reimbursement backing in Canada

Glycorex Transplantation has agreed a distribution deal with Grupo VIDA for its Glycosorb ABO technology in Brazil, as part of the Swedish medtech company's continued market expansion.

The company has completed a directed share issue as it approaches proof-of-concept data from its Phase IIa study in chronic kidney disease with anemia, expected around the turn of the year.

NordicRWE has established offices in Sweden and Denmark alongside its Oslo base, aiming to make it easier to run health data studies across the whole Nordic region – particularly in cancer, where precision medicine is splitting patients into ever-smaller subgroups.

Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible Canadian patients with mild cognitive impairment or mild dementia due to Alzheimer's disease, BioArctic's partner Eisai announced. The Swedish biotech invented the antibody and holds commercialisation rights to it in the Nordic region.

The company reported H1 2026 sales revenue up 35.2 percent year-on-year, alongside new data on its psoriasis drug candidate HRO350 that it says complement earlier results from its HeROPA trial.

The company has signed a distribution agreement with Malaysian medical device distributor OneMedik for its Glycosorb ABO product, extending the company's international footprint into a new Southeast Asian market.

Alvotech's Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio administered via prefilled syringe or autoinjector, has been accepted for review by the U.S. Food and Drug Administration.